SQZ vs. ACORQ, SCNI, PKBO, WINT, GMDAQ, SDCCQ, CMRA, BLPH, OSAP, and ADTX
Should you be buying SQZ Biotechnologies stock or one of its competitors? The main competitors of SQZ Biotechnologies include Acorda Therapeutics (ACORQ), Scinai Immunotherapeutics (SCNI), Peak Bio (PKBO), Windtree Therapeutics (WINT), Gamida Cell (GMDAQ), SmileDirectClub (SDCCQ), Comera Life Sciences (CMRA), Bellerophon Therapeutics (BLPH), ProSomnus (OSAP), and Aditxt (ADTX). These companies are all part of the "medical" sector.
Acorda Therapeutics (NASDAQ:ACORQ) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, community ranking, valuation, earnings and profitability.
SQZ Biotechnologies received 10 more outperform votes than Acorda Therapeutics when rated by MarketBeat users.
In the previous week, SQZ Biotechnologies had 1 more articles in the media than Acorda Therapeutics. MarketBeat recorded 1 mentions for SQZ Biotechnologies and 0 mentions for Acorda Therapeutics. SQZ Biotechnologies' average media sentiment score of 0.00 equaled Acorda Therapeutics'average media sentiment score.
Acorda Therapeutics has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500. Comparatively, SQZ Biotechnologies has a beta of 2.34, meaning that its stock price is 134% more volatile than the S&P 500.
SQZ Biotechnologies has lower revenue, but higher earnings than Acorda Therapeutics. SQZ Biotechnologies is trading at a lower price-to-earnings ratio than Acorda Therapeutics, indicating that it is currently the more affordable of the two stocks.
Acorda Therapeutics has a net margin of -227.75% compared to Acorda Therapeutics' net margin of -369.96%. Acorda Therapeutics' return on equity of -119.83% beat SQZ Biotechnologies' return on equity.
12.7% of Acorda Therapeutics shares are held by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are held by institutional investors. 2.6% of Acorda Therapeutics shares are held by company insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
SQZ Biotechnologies beats Acorda Therapeutics on 10 of the 13 factors compared between the two stocks.
Get SQZ Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for SQZ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SQZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SQZ Biotechnologies Competitors List
Related Companies and Tools
